ArticleACS omega2025
Nimesulide Containing Dimethoxy Benzamide: From Fever Reduction to Cancer Treatment.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drugs that are used to treat one disease can also be repurposed to treat another under the medication repurposing paradigm. The objective of this research effort is to develop new chemical compounds that selectively target the tubulin protein, which is crucial for cell movement, maintaining shape integrity, and promoting cell proliferation. Remarkably, malignant cells exhibit greater tubulin activity than benign cells; this finding raises the possibility of targeting the tubulin protein for cancer treatment. The synthesized compounds were fully characterized by physical and chemical techniques, including proton and carbon NMR, FT-IR, and mass spectroscopy, to confirm their molecular weights and chemical structures. In addition, using single-crystal X-ray diffraction, the unit-cell parameters, cell size, atom positions within the lattice, and structures of the generated compounds were confirmed, with a good yield of 90-94%. The MTT assay was used to evaluate the dose-dependent effect of the compounds on cancer cell viability. Results indicated significantly decreased viability of the MDA-MB-468 breast cancer and DU145 prostate cancer cell lines, with IC
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.